Avita Therapeutics/RCEL

$17.31

1.23%
-
1D1W1MYTD1YMAX

About Avita Therapeutics

AVITA Medical Inc. is a regenerative medicine company. The Company is engaged in the development and commercialization of devices and autologous cellular therapies for skin restoration. The Company’s RECELL System is a single use (disposable), stand-alone, battery operated, autologous cell harvesting device containing enzymatic and buffer solutions, sterile surgical instruments, and actuators to achieve the disaggregation and delivery of skin cells. The platform technology of the RECELL System allows for the preparation and delivery of Spray-On Skin Cells, an autologous cellular suspension comprised of the patient’s own skin cells necessary to regenerate natural healthy epidermis. These Spray-On Skin Cells are prepared at the point of care, providing a new way to treat thermal burns, other wounds, skin injuries or defects of the skin. The RECELL System is designed to be used at the point of care alone or in combination with autografts, depending on the depth of the burn injury.

Ticker

RCEL

Sector

Tervishoid

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

James Corbett

Employees

-

Headquarters

Valencia, United States

RCEL Metrics

BasicAdvanced
$439.58M
Market cap
-
P/E ratio
-$1.40
EPS
1.37
Beta
-
Dividend rate

What the Analysts think about RCEL

Analyst Ratings

Majority rating from 8 analysts.
Buy

Price Targets

Average projection from 6 analysts.
54.07% upside
High $40.00
Low $21.00
$17.31
Current price
$26.67
Average price target

RCEL Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-49.64% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$14.1M
3.68%
Net income
$-7M
-19.54%
Profit margin
-49.64%
-22.4%

RCEL Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 25.21%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.37
-$0.41
-$0.34
-$0.28
-
Expected
-$0.25
-$0.32
-$0.44
-$0.37
-$0.42
Surprise
47.41%
26.39%
-23.42%
-25.21%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Avita Therapeutics stock

Buy or sell Avita Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing